CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY

Masamitsu Konno, Hideshi Ishii, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

Abstract

Although cancer is a genetic disease, epigenetic alterations are involved in its initiation and progression. Previous studies showed that the introduction of endogenous small-sized, noncoding ribonucleotides including microRNA200c, -302s, and -369 resulted in the induction of cellular reprogramming. MicroRNA200c inhibits the epithelial-mesenchymal transition. MicroRNA302s induces the demethylation of the tumor suppressor gene promoter region, while microRNA369 changes cancer cell metabolism. These three types of microRNA induce cancer cellular reprogramming and modulate malignant phenotypes of human cancer cells. These results suggest that the appropriate delivery of functional small-sized ribonucleotides may be a novel approach to the treatment of human cancer.

Original languageEnglish
Pages (from-to)357-359
Number of pages3
JournalNihon Geka Gakkai zasshi
Volume116
Issue number6
Publication statusPublished - Nov 1 2015
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Konno, M., Ishii, H., Doki, Y., & Mori, M. (2015). CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY. Nihon Geka Gakkai zasshi, 116(6), 357-359.